申请人:Simmen Kenneth Alan
公开号:US20110237621A1
公开(公告)日:2011-09-29
Inhibitors of HCV replication of formula (I)
the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by
) represents an optional double bond;
X is N, CH and where X bears a double bond it is C;
R
1
is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system contains one nitrogen, and optionally one to three additional heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and wherein the remaining ring members are carbon atoms; wherein said ring system may be optionally substituted on any carbon or nitrogen ring atom with one, two, three, or four substituents;
L is a direct bond, —O—, —O—C
1-4
alkanediyl-, —O—C(═O)—, —O—C(═O)—NR
4a
— or —O—C(═O)—NR
4a
C
1-4
alkanediyl-;
R
2
is hydrogen, —OR
5
, —C(═O)OR
5
, —C(═O)R
6
, —C(═O)NR
4a
R
4b
, —C(═O)NHR
4c
, —NR
4a
R
4b
, —NHR
4c
, —NR
4a
SO
p
NR
4a
R
4b
, —NR
4a
SO
p
R
7
, or B(OR
5
)
2
;
R
3
is hydrogen, and where X is C or CH, R
3
may also be C
1-6
alkyl; n is 3, 4, 5, or 6;
p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted with one, two or three substituents;
Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, being optionally condensed with a benzene ring, and wherein the group Het as a whole may be optionally substituted with one, two or three substituents;
pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
公式(I)的HCV复制抑制剂包括其N-氧化物,盐和立体化学异构体,其中每个虚线(表示)代表可选的双键;X为N,CH,其中X带有双键时为C;R1为芳基或饱和的,部分不饱和的或完全不饱和的5或6个环成员的单环或9至12个环成员的双环杂环环系,其中所述环系含有一个氮,且可选地含有选自氧,硫和氮的一至三个附加杂原子,且所述剩余环成员为碳原子;其中所述环系可以在任何碳或氮环原子上可选地用一,二,三或四个取代基取代;L为直接键,—O—,—O—C1-4烷基二基,—O—C(═O)—,—O—C(═O)—NR4a—或—O—C(═O)—NR4aC1-4烷基二基;R2为氢,—OR5,—C(═O)OR5,—C(═O)R6,—C(═O)NR4aR4b,—C(═O)NHR4c,—NR4aR4b,—NHR4c,—NR4aSOpNR4aR4b,—NR4aSOpR7或B(OR5)2;R3为氢,且当X为C或CH时,R3也可以为C1-6烷基;n为3,4,5或6;p为1或2;芳基为苯基,萘基,茚基或1,2,3,4-四氢萘基,每个芳基可以选择地用一个,两个或三个取代基取代;Het为含有1至4个异原子的5或6个成员饱和的,部分不饱和的或完全不饱和的杂环环,每个异原子可独立地选自氮,氧和硫,可选择地与苯环融合,且作为整体的Het基团可以选择地用一个,两个或三个取代基取代;还提供了含有化合物(I)的制药组合物和制备化合物(I)的过程。公式(I)的HCV抑制剂与利托那韦的生物利用度组合也提供。